- FDA approved Lytenava, an ophthalmic version of bevacizumab, for macular degeneration, with Medicare payment determining practice switch.
- FDA approval is expected to trigger Medicare reimbursement step-up, while UnitedHealth Group covers the test ahead of guidelines.
Milestone Scientific is utilizing First Coast for reimbursement coverage and has successfully received Medicare reimbursement for its CompuFlo product.
2 reports, 1 independent
Updated Aug 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Milestone Scientific is utilizing First Coast for reimbursement coverage and has successfully received Medicare reimbursement for its CompuFlo product.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
First Coast
region of the U.S. state of Florida
Nothing else this week.
-
Medicare
US federal health insurance